 Biotech company Addis at Bio is revealing that the FDA has granted fast-track designation to its potential treatment for a certain type of cancer. ADI-270 is intended to treat patients with metastatic advanced clear cell renal cell carcinoma. And more than 40 years after its initial launch, Microsoft Notepad now has spellcheck and autocorrect features. Tech Report, Matt Mattinson.